CL2022002457A1 - Tratamiento de la infección por coronavirus y de la toxicidad asociada a las citoquinas - Google Patents

Tratamiento de la infección por coronavirus y de la toxicidad asociada a las citoquinas

Info

Publication number
CL2022002457A1
CL2022002457A1 CL2022002457A CL2022002457A CL2022002457A1 CL 2022002457 A1 CL2022002457 A1 CL 2022002457A1 CL 2022002457 A CL2022002457 A CL 2022002457A CL 2022002457 A CL2022002457 A CL 2022002457A CL 2022002457 A1 CL2022002457 A1 CL 2022002457A1
Authority
CL
Chile
Prior art keywords
cytokine
treatment
associated toxicity
coronavirus infection
infection
Prior art date
Application number
CL2022002457A
Other languages
English (en)
Inventor
Sydney David Cullis-Hill
Original Assignee
Cullis Hill Sydney David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900751A external-priority patent/AU2020900751A0/en
Application filed by Cullis Hill Sydney David filed Critical Cullis Hill Sydney David
Publication of CL2022002457A1 publication Critical patent/CL2022002457A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos novedosos para tratar o prevenir la infección por coronavirus y la toxicidad asociada a las citoquinas, incluida la toxicidad por citoquinas resultante de la activación aberrante del sistema inmunitario en la enfermedad o infección por coronavirus, como la del SARS-CoV-2.
CL2022002457A 2020-03-12 2022-09-08 Tratamiento de la infección por coronavirus y de la toxicidad asociada a las citoquinas CL2022002457A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020900751A AU2020900751A0 (en) 2020-03-12 Treatment for coronavirus infection and associated cytokine toxicity
AU2020904824A AU2020904824A0 (en) 2020-12-23 Treatment for Coronavirus infection and associated cytokine toxicity (2)

Publications (1)

Publication Number Publication Date
CL2022002457A1 true CL2022002457A1 (es) 2023-04-14

Family

ID=77670421

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002457A CL2022002457A1 (es) 2020-03-12 2022-09-08 Tratamiento de la infección por coronavirus y de la toxicidad asociada a las citoquinas

Country Status (10)

Country Link
US (2) US20230120864A1 (es)
EP (1) EP4117683A4 (es)
JP (1) JP2023517239A (es)
KR (1) KR20220159397A (es)
CN (1) CN115484964B (es)
AU (1) AU2021234945A1 (es)
BR (1) BR112022018200A2 (es)
CA (1) CA3171235A1 (es)
CL (1) CL2022002457A1 (es)
WO (1) WO2021179047A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2689848A (en) * 1951-02-06 1954-09-21 Wander Ag Dr A Salts of sulfuric acid esters of xylan
WO1994011006A1 (en) 1992-11-10 1994-05-26 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
WO1996024362A1 (fr) 1995-02-07 1996-08-15 Shiseido Company, Ltd. Agents anti-inflammatoires
US20050004071A1 (en) * 2003-04-21 2005-01-06 Comper Wayne D. Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses
EP1718315A4 (en) * 2004-02-06 2008-08-13 Univ Monash HIGH-DOSE USE AND SHORT INTERVAL OF SULFATE POLYSACCHARIDES IN THE TREATMENT OF INFECTIONS
AU2008255565B2 (en) * 2007-05-31 2013-10-24 Paradigm Biopharmaceuticals Ltd Sulphated xylans for treatment or prophylaxis of respiratory diseases
SI2178533T1 (sl) * 2007-08-24 2013-07-31 Marinomed Biotechnologie Gmbh Antivirusni sestavek, ki obsega sulfatiran polisaharid: iota-karagenan
IT1397247B1 (it) 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
HUE062108T2 (hu) 2015-07-14 2023-09-28 Marinomed Biotech Ag Vírusellenes hatású, orrdugulást megszûntetõ készítmény
WO2021203174A1 (en) * 2020-04-09 2021-10-14 Paradigm Biopharmaceuticals Ltd Treatment of acute respiratory distress syndrome (ards) with polysulfated polysaccharides

Also Published As

Publication number Publication date
JP2023517239A (ja) 2023-04-24
CN115484964B (zh) 2024-03-15
WO2021179047A1 (en) 2021-09-16
BR112022018200A2 (pt) 2022-11-29
US20230120864A1 (en) 2023-04-20
AU2021234945A1 (en) 2022-10-06
CN115484964A (zh) 2022-12-16
US11938146B2 (en) 2024-03-26
EP4117683A1 (en) 2023-01-18
US20230201250A1 (en) 2023-06-29
EP4117683A4 (en) 2024-04-24
CA3171235A1 (en) 2021-09-16
KR20220159397A (ko) 2022-12-02

Similar Documents

Publication Publication Date Title
CL2018002549A1 (es) Eliminación del virus de la hepatitis b con agentes antivirales
CO2020003000A2 (es) Tratamiento del virus del mosaico e infecciones bacterianas de plantas
EA201791886A1 (ru) Антивирусные соединения
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
AR093032A1 (es) Metodos y composiciones para controlar la infeccion viral en plantas
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
EA201991643A1 (ru) Человеческие антитела к токсину гемолизину а s.aureus
EA201792429A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
BR112017022768A2 (pt) desinfecção de tecido com ondas de choque de pressão acústica
PH12017501958B1 (en) Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
MX2021015235A (es) Compuestos utiles para el tratamiento de una infeccion por mannheimia haemolytica o histophilus somni.
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
AR122627A1 (es) Composiciones y métodos para promover la salud de las plantas
CL2020001875A1 (es) Inhibidores de pi4kiiiß
CL2021000329A1 (es) Compuestos útiles en terapia del vih
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
CL2021001903A1 (es) Tratamiento de la hepatotoxicidad
CO2022011947A2 (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih